A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia

References

• Abidi, S., Mian, I., Garcia-Ortega, I., Lecomte, T., Raedler, T., Jackson, K., … Addington, D. (2017). Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. The Canadian Journal of Psychiatry, 62(9), 635–647. doi:10.1177/0706743717720197
   PubMed Web of Science ®Google Scholar
• Adapte Collaboration. (2009). The ADAPTE process: Resource toolkit for guideline adaptation. Guidelines International Network. Retrieved from https://www.g-i-n.net/document-store/working-groups-documents/adaptation/adapte-resource-toolkit-guideline-adaptation-2-0.pdf
   Google Scholar
• Addington, D., Bouchard, R.-H., Goldberg, J., Honer, B., Malla, A., Norman, R., & Berzins, S. (2005). Clinical practice guidelines. Treatment of schizophrenia. Canadian Journal of Psychiatry, 50, 7S–57S.
   PubMedGoogle Scholar
• Angelucci, F., Aloe, L., Gruber, S. H., Fiore, M., & Mathe, A. A. (2000). Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. The International Journal of Neuropsychopharmacology, 3(1), 13–25. doi:10.1017/S1461145700001759
   PubMed Web of Science ®Google Scholar
• Argo, T. R., Crismon, M. L., Miller, A. L., Moore, T. A., Bendele, S. D., & Suehs, B. (2008). Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm. Austin, TX: Texas Department of State Health Services.
   Google Scholar
• Baandrup, L., Østrup Rasmussen, J., Klokker, L., Austin, S., Bjørnshave, T., Fuglsang Bliksted, V., … Nordentoft, M. (2016). Treatment of adult patients with schizophrenia and complex mental health needs–a national clinical guideline. Nordic Journal of Psychiatry, 70(3), 231–240. doi:10.3109/08039488.2015.1074285
   PubMed Web of Science ®Google Scholar
• Barnes, T. R, & Schizophrenia Consensus Group of the British Association for Psychopharmacology. (2011). Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England), 25(5), 567–620. doi:10.1177/0269881110391123
   PubMed Web of Science ®Google Scholar
• Birchwood, M., Smith, J., Macmillan, F., Hogg, B., Prasad, R., Harvey, C., & Bering, S. (1989). Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychological Medicine, 19(03), 649–656. doi:10.1017/S0033291700024247
   PubMedGoogle Scholar
• Bottlender, R., Jäger, M., Groll, C., Strauss, A., & Möller, H. J. (2001). Deficit states in schizophrenia and their association with the length of illness and gender. European Archives of Psychiatry and Clinical Neuroscience, 251(6), 272–278. doi:10.1007/PL00007545
   PubMed Web of Science ®Google Scholar
• Bruijnzeel, D., Suryadevara, U., & Tandon, R. (2014). Antipsychotic treatment of schizophrenia: an update. Asian Journal of Psychiatry, 11, 3–7. doi:10.1016/j.ajp.2014.08.002
   PubMedGoogle Scholar
• Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., … Keller, W. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. FOCUS, 10(2), 194–216. doi:10.1176/appi.focus.10.2.194
   Google Scholar
• Carlsson, A. (1988). The current status of the dopamine hypotesis of schizophrenia. Neuropsychopharmacology, 1(3), 179–186.
   PubMed Web of Science ®Google Scholar
• Carpenter, W. T., Jr, Buchanan, R. W., Kirkpatrick, B., Lann, H. D., Breier, A. F., & Summerfelt, A. T. (1999). Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry, 156(3), 412–418.
   PubMed Web of Science ®Google Scholar
• Casey, D. E. (2006). Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectrums, 11(S7), 25–31. doi:10.1017/S1092852900026651
   PubMedGoogle Scholar
• Cha, D. S., & McIntyre, R. S. (2012). Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opinion on Pharmacotherapy, 13(11), 1587–1598. doi:10.1517/14656566.2012.656590
   PubMed Web of Science ®Google Scholar
• Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., … Honer, W. G. (2010). Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. British Medical Journal, 341, c4024. doi:10.1136/bmj.c4024
   PubMed Web of Science ®Google Scholar
• Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 14(2), 119–136. doi:10.1002/wps.20204
   PubMed Web of Science ®Google Scholar
• Cuesta, M. J., Peralta, V., & Zarzuela, A. (1998). Illness duration and neuropsychological impairments in schizophrenia. Schizophrenia Research, 33(3), 141–150.
   PubMed Web of Science ®Google Scholar
• Davidson, M. (2018). The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues in Clinical Neuroscience, 20(3), 215.
   PubMed Web of Science ®Google Scholar
• Day, J. C., Bentall, R. P., Roberts, C., Randall, F., Rogers, A., Cattell, D., … Power, C. (2005). Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry, 62(7), 717–724. doi:10.1001/archpsyc.62.7.717
   PubMed Web of Science ®Google Scholar
• Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. A. (2017). Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatric Disease and Treatment, Volume 13, 2231–2241. doi:10.2147/NDT.S113099
   Web of Science ®Google Scholar
• DiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012). A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry, 12(1), 12–20.
   PubMedGoogle Scholar
• Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Research International, 2014, 1. doi:10.1155/2014/656370
   Web of Science ®Google Scholar
• Emsley, R., Chiliza, B., Asmal, L., & Harvey, B. H. (2013). The nature of relapse in schizophrenia. BMC Psychiatry, 13(1), 50. doi:10.1186/1471-244X-13-50
   PubMed Web of Science ®Google Scholar
• Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., … WFSBP Task Force on Treatment Guidelines for Schizophrenia. (2009a). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. The World Journal of Biological Psychiatry, 6(3), 132–191.
   Google Scholar
• Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., … WFSBP Task Force on Treatment Guidelines for Schizophrenia. (2009b). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term schizophrenia. The World Journal of Biological Psychiatry, 7(1), 5–40.
   Google Scholar
• Gaebel, W., Jänner, M., Frommann, N., Pietzcker, A., Köpcke, W., Linden, M., … Tegeler, J. (2002). First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research, 53(1–2), 145–159. doi:10.1016/S0920-9964(01)00182-7
   PubMed Web of Science ®Google Scholar
• Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., … Möller, H.-J. (2016). Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: results of the first-episode study within the German. Research Network on Schizophrenia. Schizophrenia Research, 170(1), 168–176. doi:10.1016/j.schres.2015.10.024
   PubMed Web of Science ®Google Scholar
• Gilbert, P. L., Harris, M. J., McAdams, L. A., & Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52(3), 173–188. doi:10.1001/archpsyc.1995.03950150005001
   PubMed Web of Science ®Google Scholar
• Gray, R., Rofail, D., Allen, J., & Newey, T. (2005). A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication. Journal of Advanced Nursing, 52(1), 31–37. doi:10.1111/j.1365-2648.2005.03561.x
   PubMed Web of Science ®Google Scholar
• Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., … Möller, H.-J, … & WFSBP Task Force on Treatment Guidelines for Schizophrenia. (2012). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry, 13(5), 318–378. doi:10.3109/15622975.2012.696143
   PubMed Web of Science ®Google Scholar
• Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., … Möller, H.-J, … & WFSBP Task force on Treatment Guidelines for Schizophrenia. (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The World Journal of Biological Psychiatry, 14(1), 2–44. doi:10.3109/15622975.2012.739708
   PubMed Web of Science ®Google Scholar
• Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., … Möller, H.-J, … & WFSBP Task Force on Treatment Guidelines for Schizophrenia. (2017). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia–a short version for primary care. International Journal of Psychiatry in Clinical Practice, 21(2), 82–90. doi:10.1080/13651501.2017.1291839
   PubMed Web of Science ®Google Scholar
• Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Archives of General Psychiatry, 68(2), 128–137. doi:10.1001/archgenpsychiatry.2010.199
   PubMed Web of Science ®Google Scholar
• Hui, C. L. M., Wong, G. H. Y., Tang, J. Y. M., Chang, W. C., Chan, S. K. W., Lee, E. H. M., … Chen, E. Y. H. (2013). Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research, 150(1), 297–302. doi:10.1016/j.schres.2013.08.010
   PubMed Web of Science ®Google Scholar
• Hui, C. L. M., Li, Y. K., Li, A. W. Y., Lee, E. H. M., Chang, W. C., Chan, S. K. W., … Chen, E. Y. H. (2016). Visual working memory deterioration preceding relapse in psychosis. Psychological Medicine, 46(11), 2435–2444. doi:10.1017/S0033291716000751
   PubMed Web of Science ®Google Scholar
• Hui, C. L. M., Honer, W. G., Lee, E. H. M., Chang, W. C., Chan, S. K. W., Chen, E. S. M., … Chen, E. Y. H. (2018a). Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10-year follow-up of a randomised, double-blind trial. The Lancet Psychiatry, 5(5), 432–442. doi:10.1016/S2215-0366(18)30090-7
   PubMed Web of Science ®Google Scholar
• Hui, C. L. M., Wong, A. K. H., Leung, W. W. T., Lee, E. H. M., Chan, S. K. W., Chang, W. C., … Chung, Y. C. (2018b). Psychiatrists' opinion towards medication discontinuation in remitted first‐episode psychosis: A multi‐site study of the Asian Network for Early Psychosis. Early Intervention in Psychiatry, doi:10.1111/eip.12765
   Google Scholar
• Insel, T. R. (2010). Rethinking schizophrenia. Nature, 468(7321), 187–193. doi:10.1038/nature09552
   PubMed Web of Science ®Google Scholar
• Jobe, T. H., & Harrow, M. (2005). Long-term outcome of patients with schizophrenia: a review. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 50(14), 892–900. doi:10.1177/070674370505001403
   PubMed Web of Science ®Google Scholar
• Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., … Lewis, S. W. (2006). Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63(10), 1079–1087. doi:10.1001/archpsyc.63.10.1079
   PubMed Web of Science ®Google Scholar
• Kagal, U. A., Torgal, S. S., Patil, N. M., & Malleshappa, A. (2012). Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents—a cross-sectional study. Journal of Pharmacy Practice, 25(3), 368–373. doi:10.1177/0897190012442220
   PubMedGoogle Scholar
• Kane, J. M., Leucht, S., & Carpenter, D. (2003). Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders. The Journal of Clinical Psychiatry, 64, 12.
   Web of Science ®Google Scholar
• Kayo, M., Tassell, I., Hiroce, V., Menezes, A., & Elkis, H. (2012). Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis? Clinics, 67(12), 1479–1482.
   PubMed Web of Science ®Google Scholar
• Keshavan, M. S., Roberts, M., & Wittmann, D. (2006). Guidelines for clinical treatment of early course schizophrenia. Current Psychiatry Reports, 8(4), 329–334. doi:10.1007/s11920-006-0070-7
   PubMedGoogle Scholar
• Kikkert, M. J., Schene, A. H., Koeter, M. W. J., Robson, D., Born, A., Helm, H., … Gray, R. J. (2006). Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophrenia Bulletin, 32(4), 786–794. doi:10.1093/schbul/sbl011
   PubMed Web of Science ®Google Scholar
• Kinon, B. J., Chen, L., Ascher-Svanum, H., Stauffer, V. L., Kollack-Walker, S., Zhou, W., … Kane, J. M. (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of Schizophrenia. Neuropsychopharmacology, 35(2), 581–590. doi:10.1038/npp.2009.164
   PubMed Web of Science ®Google Scholar
• Klein, W. M., & Stefanek, M. E. (2007). Cancer risk elicitation and communication: lessons from the psychology of risk perception. CA: A Cancer Journal for Clinicians, 57(3), 147–167.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010). The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin, 36(1), 94–103. doi:10.1093/schbul/sbp130
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., … Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3), 199–214. doi:10.1001/archpsyc.1994.03950030035004
   PubMed Web of Science ®Google Scholar
• Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., … Steinwachs, D. M. (2004a). The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin, 30(2), 193–217. doi:10.1093/oxfordjournals.schbul.a007071
   PubMed Web of Science ®Google Scholar
• Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O., … Cook, I. (2004b). Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161(2 Suppl), 1–56.
   PubMed Web of Science ®Google Scholar
• Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35(1), 51–68. doi:10.1016/S0920-9964(98)00105-4
   PubMed Web of Science ®Google Scholar
• Leucht, S., Barnes, T. R., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003). Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry, 160(7), 1209–1222. doi:10.1176/appi.ajp.160.7.1209
   PubMed Web of Science ®Google Scholar
• Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009a). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry, 14(4), 429–447. doi:10.1038/sj.mp.4002136
   PubMed Web of Science ®Google Scholar
• Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009b). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet, 373(9657), 31–41. doi:10.1016/S0140-6736(08)61764-X
   PubMed Web of Science ®Google Scholar
• Leucht, S., Heres, S., Kissling, W., & Davis, J. M. (2011). Evidence-based pharmacotherapy of schizophrenia. The International Journal of Neuropsychopharmacology, 14(02), 269–284. doi:10.1017/S1461145710001380
   PubMedGoogle Scholar
• Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet, 379(9831), 2063–2071. doi:10.1016/S0140-6736(12)60239-6
   PubMed Web of Science ®Google Scholar
• Lieberman, J., Jody, D., Geisler, S., Alvir, J., Loebel, A., Szymanski, S., … Borenstein, M. (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry, 50(5), 369–376. doi:10.1001/archpsyc.1993.01820170047006
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A. (1999). Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry, 46(6), 729–739. doi:10.1016/S0006-3223(99)00147-X
   PubMed Web of Science ®Google Scholar
• Liberman, R. P., Kopelowicz, A., Ventura, J., & Gutkind, D. (2002). Operational criteria and factors related to recovery from schizophrenia. International Review of Psychiatry, 14(4), 256–272. doi:10.1080/0954026021000016905
   Web of Science ®Google Scholar
• Llorca, P. M. (2008). Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Research, 161(2), 235–247. doi:10.1016/j.psychres.2007.07.012
   PubMed Web of Science ®Google Scholar
• Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy, 21(9), 754–769. doi:10.18553/jmcp.2015.21.9.754
   PubMed Web of Science ®Google Scholar
• Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., … Schooler, N. R. (2002). The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin, 28(1), 5–16. doi:10.1093/oxfordjournals.schbul.a006926
   PubMed Web of Science ®Google Scholar
• Masand, P. S., Roca, M., Turner, M. S., & Kane, J. M. (2009). Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. The Primary Care Companion to the Journal of Clinical Psychiatry, 11(4), 147–154. doi:10.4088/PCC.08r00612
   PubMedGoogle Scholar
• McGorry, P. D. (2007). Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. American Journal of Psychiatry, 164(6), 859–860. doi:10.1176/ajp.2007.164.6.859
   PubMed Web of Science ®Google Scholar
• McGorry, P., Bates, T., & Birchwood, M. (2013). Designing youth mental health services for the 21st century: examples from Australia, Ireland and the UK. British Journal of Psychiatry, 202(s54), s30–s35. doi:10.1192/bjp.bp.112.119214
   Google Scholar
• Menezes, N. M., Arenovich, T., & Zipursky, R. B. (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine, 36(10), 1349–1362. doi:10.1017/S0033291706007951
   PubMed Web of Science ®Google Scholar
• Murphy, B. M., Burke, J. G., Bray, J. C., Walsh, D., & Kendler, K. S. (1994). An analysis of the clinical features of familial schizophrenia. Acta Psychiatrica Scandinavica, 89(6), 421–427.
   PubMed Web of Science ®Google Scholar
• NICE (2014). Psychosis and schizophrenia in adults: prevention and management. United Kingdom: National Institute for Health and Care Excellence (NICE), 1–55.
   Google Scholar
• Ohlsen, R. I., O'Toole, M. S., Purvis, R. G., Walters, J. T., Taylor, T. M., Jones, H. M., & Pilowsky, L. S. (2004). Clinical effectiveness in first-episode patients. European Neuropsychopharmacology, 14, S445–S451. doi:10.1016/j.euroneuro.2004.08.003
   PubMed Web of Science ®Google Scholar
• Olfson, M., Mechanic, D., Hansell, S., Boyer, C. A., Walkup, J., & Weiden, P. J. (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services, 51(2), 216–222. doi:10.1176/appi.ps.51.2.216
   PubMed Web of Science ®Google Scholar
• Osser, D. N., Roudsari, M. J., & Manschreck, T. (2013). The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harvard Review of Psychiatry, 21(1), 18–40.
   PubMed Web of Science ®Google Scholar
• Ossowska, K., Pietraszek, M., Wardas, J., Nowak, G., & Wolfarth, S. (1999). Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 359(4), 280–287. doi:10.1007/PL00005353
   PubMed Web of Science ®Google Scholar
• Ozaki, T., Mui, K., & Yamagami, S. (1999). Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression. European Journal of Pharmacology, 369(1), 133–143. doi:10.1016/S0014-2999(99)00059-X
   PubMed Web of Science ®Google Scholar
• Ozaki, T. (2000). Comparative effects of dopamine D1 and D2 receptor antagonists on nerve growth factor protein induction. European Journal of Pharmacology, 402(1–2), 39–44. doi:10.1016/S0014-2999(00)00493-3
   PubMed Web of Science ®Google Scholar
• Peroutka, S. J. (1994). Molecular biology of serotonin (5-HT) receptors. Synapse (New York, N.Y.), 18(3), 241–260. doi:10.1002/syn.890180310
   PubMed Web of Science ®Google Scholar
• Purdon, S. E., Labelle, A., & Boulay, L. (2001). Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophrenia Research, 48(1), 57–67. doi:10.1016/S0920-9964(00)00101-8
   PubMed Web of Science ®Google Scholar
• Raskin, S. A., Maye, J., Rogers, A., Correll, D., Zamroziewicz, M., & Kurtz, M. (2014). Prospective memory in schizophrenia: Relationship to medication management skills, neurocognition, and symptoms in individuals with schizophrenia. Neuropsychology, 28(3), 359–365. doi:10.1037/neu0000040
   PubMed Web of Science ®Google Scholar
• Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017). Guidelines for the pharmacotherapy of schizophrenia in adults. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 62(9), 604–616. doi:10.1177/0706743717720448
   PubMed Web of Science ®Google Scholar
• Robinson, D. G., Woerner, M. G., Alvir, J. M., Geisler, S., Koreen, A., Sheitman, B., … Lieberman, J. A. (1999). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. The American Journal of Psychiatry, 156(4), 544–549. doi:10.1176/ajp.156.4.544
   PubMed Web of Science ®Google Scholar
• Roth, B. L., Sheffler, D., & Potkin, S. G. (2003). Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? Clinical Neuroscience Research, 3(1–2), 108–117. doi:10.1016/S1566-2772(03)00021-5
   Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders, & Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39(1–2), 1–30.
   PubMed Web of Science ®Google Scholar
• Samalin, L., Charpeaud, T., Blanc, O., Heres, S., & Llorca, P. M. (2013). Clinicians’ attitudes toward the use of long-acting injectable antipsychotics. The Journal of Nervous and Mental Disease, 201(7), 553–559. doi:10.1097/NMD.0b013e31829829c4
   PubMed Web of Science ®Google Scholar
• Schoepf, D., Uppal, H., Potluri, R., & Heun, R. (2014). Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. European Archives of Psychiatry and Clinical Neuroscience, 264(1), 3–28. doi:10.1016/S0924-9338(14)77570-4
   PubMed Web of Science ®Google Scholar
• SIGN (2013). Management of schizophrenia. Edinburgh: Scottish Intercollegiate Guidelines Network, 1–71.
   Google Scholar
• Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012). Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophrenia Research, 134(2–3), 219–225. doi:10.1016/j.schres.2011.11.021
   PubMed Web of Science ®Google Scholar
• Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008). Schizophrenia “just the facts”: What we know in 2008: Part 1: Overview. Schizophrenia Research, 100(1–3), 4–19. doi:10.1016/j.schres.2008.01.022
   PubMed Web of Science ®Google Scholar
• Taylor, D., Paton, C., & Kapur, S. (2009). The Maudsley Prescribing Guidelines. London: CRC Press.
   Google Scholar
• Thornley, B., Rathbone, J., Adams, C. E., & Awad, G. (2003). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, (2), 1465–1858.
   Google Scholar
• van Haren, N. E., Schnack, H. G., Cahn, W., van den Heuvel, M. P., Lepage, C., Collins, L., … Kahn, R. S. (2011). Changes in cortical thickness during the course of illness in schizophrenia. Archives of General Psychiatry, 68(9), 871–880. doi:10.1001/archgenpsychiatry.2011.88
   PubMed Web of Science ®Google Scholar
• Velligan, D. I., Wang, M., Diamond, P., Glahn, D. C., Castillo, D., Bendle, S., … Miller, A. L. (2007). Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services, 58(9), 1187–1192. doi:10.1176/appi.ps.58.9.1187
   PubMed Web of Science ®Google Scholar
• Verma, S., Chan, L. L., Chee, K. S., Chen, H., Chin, S. A., Chong, S. A., … Kwek, S. K. (2011). Ministry of Health Clinical Practice Guidelines: Schizophrenia. Singapore Medical Journal, 52(7), 521–525.
   PubMed Web of Science ®Google Scholar
• Vollenweider, F. X. (1998). Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry, 31(S 2), 92–103. doi:10.1055/s-2007-979353
   PubMedGoogle Scholar
• Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., … Murray, C. J. (2015). Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 386(9995), 743–800.
   PubMed Web of Science ®Google Scholar
• Weiden, P. J. (2007). EPS profiles: the atypical antipsychotics: are not all the same. Journal of Psychiatric Practice®, 13(1), 13–24. doi:10.1097/00131746-200701000-00003
   PubMedGoogle Scholar
• Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., … Vos, T. (2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet, 382(9904), 1575–1586. doi:10.1016/S0140-6736(13)61611-6
   PubMed Web of Science ®Google Scholar
• Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998). Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophrenia Bulletin, 24(1), 75–85. doi:10.1093/oxfordjournals.schbul.a033315
   PubMed Web of Science ®Google Scholar
• Working Group of the Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder. (2009). Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder (pp. 114–139). Barcelona: Catalan Agency for Health Technology Assessment and Research.
   Google Scholar
• World Health Organization (2008). Leading causes of years lost due to disability in 2004. In Global burden of disease 2004 update (pp. 36–37). Geneva: WHO Press.
   Google Scholar
• Zhang, R., Wei, Q., Kang, Z., Zalesky, A., Li, M., Xu, Y., … Huang, R. (2015). Disrupted brain anatomical connectivity in medication-naïve patients with first-episode schizophrenia. Brain Structure and Function, 220(2), 1145–1159.
   PubMed Web of Science ®Google Scholar